Age, Biography and Wiki

Nathaniel David was born on 27 December, 1967 in San Francisco, California, U.S., is an American scientist and entrepreneur. Discover Nathaniel David's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 56 years old?

Popular As N/A
Occupation N/A
Age 56 years old
Zodiac Sign Capricorn
Born 27 December 1967
Birthday 27 December
Birthplace San Francisco, California, U.S.
Nationality United States

We recommend you to check the complete list of Famous People born on 27 December. He is a member of famous Entrepreneur with the age 56 years old group.

Nathaniel David Height, Weight & Measurements

At 56 years old, Nathaniel David height not available right now. We will update Nathaniel David's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

Nathaniel David Net Worth

His net worth has been growing significantly in 2023-2024. So, how much is Nathaniel David worth at the age of 56 years old? Nathaniel David’s income source is mostly from being a successful Entrepreneur. He is from United States. We have estimated Nathaniel David's net worth, money, salary, income, and assets.

Net Worth in 2024 $1 Million - $5 Million
Salary in 2024 Under Review
Net Worth in 2023 Pending
Salary in 2023 Under Review
House Not Available
Cars Not Available
Source of Income Entrepreneur

Nathaniel David Social Network

Instagram
Linkedin
Twitter Nathaniel David Twitter
Facebook
Wikipedia Nathaniel David Wikipedia
Imdb

Timeline

Nathaniel David is an American scientist and entrepreneur who co-founded a series of technology companies in the biotechnology and sustainable energy sectors, including Syrrx (acquired by Takeda Pharmaceutical Company), Achaogen (NASDAQ: AKAO), Kythera Biopharmaceuticals (NASDAQ: KYTH, acquired by Allergan), Sapphire Energy and Unity Biotechnology.

These companies have collectively raised more than $1.5 billion in financing.

David earned an A.B. in Biology from Harvard University and a Ph.D. in Molecular and Cellular Biology from University of California, Berkeley.

He co-founded his first company, Syrrx, during the final year of his doctoral work at UC Berkeley.

Syrrx was the first company in the world to build a high-throughput structural biology ‘factory,’ using automation, nano-scale experiments, and crystallography to make the determination of atomic structures of proteins easier, faster, and cheaper.

2002

In 2002, while at Syrrx, he was named to the MIT Technology Review TR35 as one of the top 35 innovators in the world under the age of 35.

2005

In 2005, Syrrx was acquired by Takeda, and the FDA-approved drug Nesina arose from Syrrx discovery efforts.

David left Syrrx to co-found Achaogen (NASDAQ: AKAO), an antibiotic company, and Kythera Biopharmaceticals (NASDAQ: KYTH).

He served as Chief Science Officer of Kythera while the company created a now-FDA-approved injectable drug Kybella that triggers the selective destruction of fat cells.

2007

In 2007, while still serving as Chief Science Officer at Kythera, David co-founded Sapphire Energy, a company with a mission to develop renewable, algae-derived transportation fuels that are 100% compliant with the existing energy infrastructure.

2010

In 2010, the company began construction of the world's first commercial algal bio-refinery, a project that was awarded more than $100 million in federal funding.

2011

In 2011, David co-founded Unity Biotechnology (NASDAQ: UBX), a company dedicated to lengthening human healthspan by selectively clearing senescent cells from the body.

UNITY is creating medicines that target multiple diseases of aging.

David is currently the President of Unity Biotechnology.

2012

Kythera went public in October 2012 on the NASDAQ exchange under the ticker symbol KYTH, and was acquired by Allergan in 2015 for $2.1 billion.

Achaogen's antibiotic plazomicin is effective against multidrug-resistant infections of Enterobacteriaceae.

2016

In 2016, plazomicin demonstrated noninferiority for urinary tract infections (UTIs) in a pivotal phase III trial against colistin, and against meropenem for complicated UTIs and acute pyelonephritis.

2018

The U.S. Food and Drug Administration (FDA) approved plazomicin for adults with complicated UTIs and limited or no alternative treatment options in 2018; it is now sold under the brand name Zemdri.

2019

In April 2019, Achaogen declared bankrupt.